Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGEN NASDAQ:OGI NASDAQ:TNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGENCompugen$1.54-3.1%$1.60$1.13▼$2.66$137.43M2.57365,196 shs255,857 shsOGIOrganigram Global$1.45-0.7%$1.37$0.85▼$2.08$194.21M1.36664,773 shs492,842 shsTNGXTango Therapeutics$6.77-1.3%$4.12$1.03▼$12.02$733.83M1.631.62 million shs1.26 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGENCompugen0.00%-3.14%-6.67%+4.76%-17.20%OGIOrganigram Global0.00%0.00%+9.85%+35.51%-14.20%TNGXTango Therapeutics0.00%+14.17%+41.04%+424.81%-30.64%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCGENCompugen1.0586 of 5 stars3.52.00.00.00.00.00.0OGIOrganigram Global0.532 of 5 stars0.01.00.00.00.60.02.5TNGXTango Therapeutics1.6212 of 5 stars3.51.00.00.01.91.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGENCompugen 3.00Buy$4.00159.74% UpsideOGIOrganigram Global 0.00N/AN/AN/ATNGXTango Therapeutics 3.00Buy$10.5055.10% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGENCompugen$27.59M4.98N/AN/A$0.62 per share2.48OGIOrganigram Global$117.47M1.65N/AN/A$2.07 per share0.70TNGXTango Therapeutics$40.99M17.90N/AN/A$1.86 per share3.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGENCompugen-$14.23M-$0.16N/AN/AN/A-51.27%-24.51%-12.19%8/5/2025 (Estimated)OGIOrganigram Global-$33.39M$0.1014.50N/AN/A8.05%-5.93%-4.39%8/12/2025 (Estimated)TNGXTango Therapeutics-$130.30M-$1.22N/AN/AN/A-322.67%-62.75%-39.94%8/6/2025 (Estimated)Latest TNGX, OGI, and CGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q3 2025OGIOrganigram Global-$0.01N/AN/AN/A$68.04 millionN/A8/6/2025Q2 2025TNGXTango Therapeutics-$0.35N/AN/AN/A$6.41 millionN/A8/5/2025Q2 2025CGENCompugen-$0.07N/AN/AN/A$3.95 millionN/A5/19/2025Q1 2025CGENCompugen-$0.06-$0.08-$0.02-$0.08$3.70 million$2.28 million5/12/2025Q1 2025TNGXTango Therapeutics-$0.34-$0.36-$0.02-$0.36$6.73 million$5.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGENCompugenN/AN/AN/AN/AN/AOGIOrganigram GlobalN/AN/AN/AN/AN/ATNGXTango TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGENCompugenN/A5.095.09OGIOrganigram GlobalN/A3.421.90TNGXTango TherapeuticsN/A6.266.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGENCompugen12.22%OGIOrganigram Global34.63%TNGXTango Therapeutics78.99%Insider OwnershipCompanyInsider OwnershipCGENCompugen9.50%OGIOrganigram Global0.09%TNGXTango Therapeutics7.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGENCompugen7089.24 million80.76 millionOptionableOGIOrganigram Global860133.94 million133.82 millionOptionableTNGXTango Therapeutics90108.39 million100.26 millionOptionableTNGX, OGI, and CGEN HeadlinesRecent News About These CompaniesTango Therapeutics (NASDAQ:TNGX) Stock Price Up 9.1% - Time to Buy?July 18 at 9:26 PM | marketbeat.comTNGX - Tango Therapeutics Inc News - MorningstarJuly 16, 2025 | morningstar.comMDoes Tango Therapeutics (TNGX) Have the Potential to Rally 75.89% as Wall Street Analysts Expect?July 14, 2025 | zacks.comTango Therapeutics (NASDAQ:TNGX) Shares Down 4.6% - Time to Sell?July 11, 2025 | marketbeat.comTango Therapeutics (NASDAQ:TNGX) Trading Up 7.1% - What's Next?July 9, 2025 | marketbeat.comHC Wainwright Issues Positive Estimate for TNGX EarningsJuly 2, 2025 | marketbeat.comTango Therapeutics doses first patient in cancer drug combo trialJune 29, 2025 | uk.investing.comTango Therapeutics, Inc. (NASDAQ:TNGX) Receives Average Rating of "Buy" from AnalystsJune 28, 2025 | marketbeat.comTango Therapeutics Shares Climb After First Patient Dosed in Pancreatic, Lung Cancer TrialJune 27, 2025 | marketwatch.comTango Therapeutics (NASDAQ:TNGX) Trading Up 6.5% - Should You Buy?June 27, 2025 | marketbeat.comTango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung CancerJune 27, 2025 | globenewswire.comTango Therapeutics (NASDAQ:TNGX) Shares Down 8.3% - Should You Sell?June 25, 2025 | marketbeat.comTango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last? - NasdaqJune 25, 2025 | nasdaq.comExchange Traded Concepts LLC Purchases 47,901 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX)June 25, 2025 | marketbeat.comTango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last?June 23, 2025 | zacks.comTango Therapeutics’ SWOT analysis: stock poised for growth amid clinical trialsJune 16, 2025 | investing.comTango Therapeutics: PRMT5 Data Readout Due In 2025 Is CriticalJune 6, 2025 | seekingalpha.comTango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare ConferenceMay 27, 2025 | finance.yahoo.comTango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare ConferenceMay 27, 2025 | globenewswire.comTango Therapeutics starts trial for brain cancer drugMay 23, 2025 | uk.investing.comTango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid TumorsMay 21, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Hot Tech Stocks Showing Bullish Price Action Right NowBy Thomas Hughes | July 11, 2025View 3 Hot Tech Stocks Showing Bullish Price Action Right NowUber and Tesla Surge on Robotaxis, Analyst Touts Texas RidesBy Leo Miller | June 25, 2025View Uber and Tesla Surge on Robotaxis, Analyst Touts Texas RidesWhy Prologis May Be the Smartest Backdoor Bet on AI Real EstateBy Chris Markoch | July 17, 2025View Why Prologis May Be the Smartest Backdoor Bet on AI Real EstateGeospace Stock Skyrockets After Major Petrobras ContractBy Jeffrey Neal Johnson | June 24, 2025View Geospace Stock Skyrockets After Major Petrobras ContractThe Trade Desk's S&P 500 Entry: Ad-Tech Stock as a Core Holding?By Jeffrey Neal Johnson | July 17, 2025View The Trade Desk's S&P 500 Entry: Ad-Tech Stock as a Core Holding?TNGX, OGI, and CGEN Company DescriptionsCompugen NASDAQ:CGEN$1.54 -0.05 (-3.14%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.54 -0.01 (-0.32%) As of 07/18/2025 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.Organigram Global NASDAQ:OGI$1.45 -0.01 (-0.68%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.46 +0.01 (+0.69%) As of 07/18/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.Tango Therapeutics NASDAQ:TNGX$6.77 -0.09 (-1.31%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$6.68 -0.09 (-1.26%) As of 07/18/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
